Supi Pharmaceutical (Guangzhou) Co., Ltd.

To describe the safety, efficacy, and compliance of Chinese HT-1 patients receiving nitisinone in routine clinical care.

The primary objective of this study is to demonstrate the efficacy of Emapalumab in the treatment of patients with symptomatic juvenile idiopathic arthritis and adult-onset Still's disease with secondary macrophage activation syndrome and children and adults with systemic lupus erythematosus with secondary macrophage activation syndrome. The secondary objectives of this study are to demonstrate the efficacy of Emapalumab in the tapering of glucocorticoids; to evaluate the duration of the onset of Emapalumab treatment; to evaluate the efficacy of Emapalumab in overall remission; to evaluate the sustained efficacy of Emapalumab treatment; to evaluate the survival of patients after Emapalumab treatment; to evaluate the safety and tolerability of Emapalumab; to evaluate the patient-reported outcomes of macrophage activation syndrome in patients treated with Emapalumab; to determine the pharmacokinetic characteristics of Emapalumab; to determine the pharmacodynamic characteristics of Emapalumab; and to determine the immunogenicity of Emapalumab.

The primary objective of this study is to collect safety data of imalimumab in Chinese patients with previously treated pHLH. The secondary objective of this study is to collect efficacy data of imalimumab in Chinese patients with previously treated pHLH.